Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.

S Appleton1, P Poole, B Smith

  • 1Queen Elizabeth Hospital, Dept. of Medicine, Woodville Rd., Woodville, Adelaide, Australia 5011. sappleto@medicine.adelaide.edu au

The Cochrane Database of Systematic Reviews
|July 21, 2006
PubMed
Summary

Long-acting beta-agonists (LABAs) like salmeterol offer modest lung function improvements for COPD patients with poor bronchodilator reversibility. Salmeterol 50 mcg BID consistently reduced exacerbations, a key benefit for frequent symptom deteriorations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Irish General Practitioner referrals to psychological therapies.

Irish journal of psychological medicine·2018
Same author

Providing patients with reviews of evidence about COPD treatments: a controlled trial of outcomes.

Chronic respiratory disease·2006
Same author

Printed patient education interventions to facilitate shared management of chronic disease: a literature review.

Internal medicine journal·2005
Same author

'Papillomatization' and 'malignant transformation' of an abscess cavity in a 25-year old man with recurrent respiratory papillomatosis who may have had Lemierre syndrome.

Chronic respiratory disease·2005
Same author

Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation.

The Cochrane database of systematic reviews·2002
Same author

Impact and aetiology of respiratory infections, asthma and airway disease in Australian Aborigines.

Journal of paediatrics and child health·2001

Area of Science:

  • Pulmonology
  • Pharmacology
  • Clinical Trials

Background:

  • Chronic obstructive pulmonary disease (COPD) involves airflow limitation with variable reversibility.
  • Many COPD patients show limited response to short-acting bronchodilators.
  • Long-acting bronchodilators are often recommended despite limited reversibility data.

Purpose of the Study:

  • To assess the efficacy of long-acting beta-2 adrenoceptor agonists (LABAs) in COPD patients with poor short-acting bronchodilator reversibility.
  • Evaluate LABA effectiveness in improving lung function and reducing exacerbations.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) comparing inhaled LABAs (salmeterol, formoterol) with placebo.
  • Included studies were a minimum of four weeks in duration for stable COPD patients.

Related Experiment Videos

  • Data extraction and quality assessment were performed independently by two authors.

    • Main Results:

    • Salmeterol 50 mcg twice daily (BID) significantly improved forced expiratory volume in 1 second (FEV1) by 51 ml and peak expiratory flow (PEF).
    • Reduced use of supplemental short-acting bronchodilators and improved St. George's Respiratory Questionnaire scores were observed with salmeterol.
    • A significant reduction in exacerbations was noted (number needed to treat: 21), but exercise tolerance showed no significant difference.

    Conclusions:

    • Salmeterol 50 mcg BID provides modest lung function improvements in COPD patients with poor reversibility.
    • Consistent reduction in exacerbations is a significant benefit for patients experiencing frequent symptom deterioration.
    • Evidence for other LABA dosages or formoterol was insufficient to guide clinical practice.